News | June 08, 2024
GSK acquires oligonucleotide drug startup Elsie
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Subscribe To Our Newsletter & Stay Updated
